Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
India is emerging as an economic superpower, highlighted David Ricks, CEO, Eli Lilly, a pharmaceutical company, following a ...
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...